Background: Recent efficacy studies of asthma biologics have included highly
facilitate a more precise approach to treatment. Recent studies have suggested that clinical and biologic markers of asthma severity predict variations in response to biologic therapies for the treatment of asthma. [3] [4] [5] Our previous work from evaluations of omalizumab clinical trial data has indicated that higher levels of type 2 (T2) asthma biomarkers, including fractional exhaled nitric oxide (FeNO), serum periostin, and blood eosinophil counts, predict a better response to omalizumab. 3 however, they did not show clear benefits in asthma subpopulations without such exacerbation history or with lower blood eosinophil counts. [6] [7] [8] [9] [10] [11] Furthermore, specific thresholds of blood eosinophil counts have been incorporated as inclusion criteria for treatment with other biologic agents [12] [13] [14] or inclusion criteria have been applied with enriching effects on the population being studied. For example, phase II and III trials of biologic therapies targeting the IL-5 pathway enrolled patients with ≥2 or ≥3 exacerbations in the previous year, background use of long-acting beta-agonists (LABAs) ≥90%, baseline peripheral blood eosinophil count ≥300/lL, and percentage of predicted prebronchodilator forced expiratory volume in 1 second (FEV 1 ) <62.5. 4, 6, 12, 15 Elevated blood eosinophil counts have been associated with more severe asthma and predict a higher risk of asthma exacerbations in patients already treated with inhaled corticosteroids (ICS). 16, 17 Elevated blood eosinophils in patients with allergic asthma suggest an underlying T2 asthma phenotype, also known as T2 high asthma. T2 inflammation is driven by a specific profile of cytokines and mediators, including IgE, IL-4, IL-5, IL-9, IL-13, and IL-33.
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Although blood eosinophil count is an imperfect surrogate for airway eosinophils and may not be the optimal evaluation of T2 status, the relative ease of obtaining this measurement at the point of care has facilitated its use in clinical research. As newer biologic agents become available for asthma, it will be important to understand the extent to which these agents compare with existing therapies in the context of similar biomarkers and asthma severity.
We examined data from two pivotal trials 22, 23 that constituted the basis for the regulatory approval of omalizumab in allergic asthma to identify whether baseline blood eosinophil counts predicted superior response to this therapy, using both specific cut points and a range of eosinophil levels. Because these pivotal trials included patients with either moderate or severe persistent allergic asthma, we examined the response to omalizumab in patients as a function of baseline asthma severity.
2 | ME TH ODS
| Study design
We examined pooled data from two pivotal, phase III, double-blind, placebo-controlled registration trials of omalizumab (N = 1071): 525 patients in study 1 22 and 546 patients in study 2. 23 Each study was conducted in two phases after screening and randomization: a The primary end point for each study was the number of asthma exacerbations, defined as a requirement for systemic corticosteroids or a doubling of the ICS dose. 22, 23 This analysis examined the annualized rate of asthma exacerbations during the 16-week ICS dose-stable phase of the studies, not during the 12-week ICS dosereduction phase.
| Study definitions
Since the pivotal trials were conducted, consensus recommendations have indicated that a requirement for systemic corticosteroids is the critical element in defining a severe asthma exacerbation. 24 Thus, in defining the end point for the current analysis, we used the number of asthma exacerbations requiring ≥3 days of systemic corticosteroids during the 16-week ICS dose-stable phase of the studies as the exacerbation definition.
Type 2 (T2) inflammation status was defined based on baseline blood eosinophil levels (eosinophil count <300/lL [low] vs ≥300/lL
[high]). We chose a threshold eosinophil count of 300/lL based on the precedent set by studies of omalizumab and other biologic agents. 3, 4, 12, 14, 15 In addition, we examined exacerbation rate reductions associated with omalizumab by baseline blood eosinophil strata of ≥200/lL, ≥300/lL, and ≥400/lL, as described by Castro et al. 12 Asthma severity was categorized separately as emergency asthma treatment or asthma hospitalization in the year before baseline, FEV 1 at baseline (FEV 1 <65% vs FEV 1 ≥65% predicted), use of inhaled beclomethasone dipropionate (<600 lg/day vs ≥600 lg/day), and LABA use (yes vs no). The thresholds for FEV 1 and beclomethasone were based on median cohort values.
| Statistical analysis
CIs and P values for comparisons of exacerbation rates were calculated using unadjusted negative binomial models. Separate analyses using these models were conducted on subgroups to evaluate the potential effects of omalizumab on exacerbations in patients stratified by eosinophil counts and asthma severity.
We plotted annualized exacerbation rates in the omalizumab and placebo groups as a function of eosinophil counts based on a negative binomial regression model developed using the data from the omalizumab pivotal trials, and based on a similar previously published analysis by Pavord et al 6 in the study of an anti-IL-5 agent. Because eosinophils are log-normally distributed, this variable was incorporated into the regression model after log-transformation, with an
interaction term between eosinophils and treatment group incorporated into modeling.
To examine how omalizumab efficacy might have varied in the hypothetical case that a more enriched population was enrolled into the original pivotal studies, a statistical simulation technique was employed. Negative binomial regression models were developed to predict asthma exacerbation rates in the omalizumab trials, with a subsequent imputation into the models of the actual observed estimates published from a recent anti-IL-5 trial. 6 Factors selected for the model were prespecified based on those available in both the omalizumab and mepolizumab (DREAM) studies: age, sex, race, body mass index, 3 | RESULTS
| Patient population
Baseline demographic and clinical characteristics were similar in the omalizumab and placebo groups ( Table 1) . The omalizumab and placebo groups had a mean (SD) age of 39.7 (13.8) and 39.0 (13.7) years, respectively, and the majority (55%) of patients were female. Asthma was long-standing in these patients, with a mean (SD) duration of 20.5 (13.6) and 20.8 (14.0) years for patients in the omalizumab and placebo groups, respectively. A minority (~15%) of patients had previously been treated with a LABA and nearly 40% had received emergency asthma treatment in the year preceding enrollment.
| Effects of omalizumab vs placebo on asthma exacerbations overall
The rate of exacerbations requiring ≥3 days of systemic corticosteroid treatment was 0.066 in patients receiving omalizumab and 0.147 in patients receiving placebo, representing a relative rate reduction in patients receiving omalizumab of 55% (95% CI, 32%-70%; P = .002).
| Effects of omalizumab vs placebo on asthma exacerbations based on blood eosinophils and asthma severity
Exacerbation reduction was more pronounced with omalizumab vs placebo in patients with higher eosinophil counts (eosinophil count ≥300/lL) and with more severe asthma (history of emergency asthma treatment, history of hospitalization, FEV 1 <65% predicted, requirement for beclomethasone ≥600 lg/day, requirement for LABA use) ( Figure 1 ).
Mean exacerbation rate reductions associated with omalizumab by baseline blood eosinophil strata were as follows: ≥200/lL, 55%
(95% CI, 25%-73%; P = .002); ≥300/lL, 67% (95% CI, 36%-84%; P = .001); and ≥400/lL, 74% (95% CI, 40%-88%; P = .001) (Figure 2 ).
Asthma exacerbation rates with placebo and omalizumab as a function of eosinophil counts were graphed based on a negative binomial regression model ( Figure 3) . The model shows that the efficacy benefit of omalizumab increases with increasing baseline eosinophil count, suggesting that response to omalizumab is observed across a wide range of eosinophil levels but is better with higher eosinophil levels.
3.4 | Use of statistical simulations to attempt to determine omalizumab efficacy in a more enriched population of patients
The results of these simulations revealed an increase to 57% from the original unadjusted exacerbation rate reduction of 53%, when adjusting only for main effects, and up to 86% when also incorporating interactions into the model (Table 2 ). This suggests that if the original omalizumab trials had enrolled a more enriched population, similar to that enrolled in the more recent anti-IL-5 trial, 6 the efficacy would have been greater than was observed. Indeed, the efficacy benefit of omalizumab was observed across a wide range of eosinophil levels, rather than specific cut points.
Additionally, simulation analyses indicated that the efficacy of omalizumab would have been greater had the original omalizumab trials enrolled a more enriched population, similar to that enrolled in the more recent anti-IL-5 trials. 
| 493
Our graph of exacerbation rates as a function of eosinophil counts using a negative binomial regression model ( Figure 3 ) showed a pattern similar to that seen in the DREAM study with mepolizumab. 6 Our analysis not only confirms findings from our previous study demonstrating that blood eosinophil counts predict a significant response to omalizumab in patients with severe allergic asthma, 5 but also expands those findings to include a wider range of eosinophil counts, rather than applying specific cut points. Other studies of biologic therapies have examined efficacy based on eosinophil cut points; however, the studies varied considerably in the patient populations examined, study durations, and dosing schedules Exacerbation rate over the 16-wk inhaled corticosteroid-stable phase, adjusted for age, sex, race, body mass index, tobacco use status, asthma duration, spirometry value, Asthma Quality of Life Questionnaire score, LABA use, blood eosinophil count, and asthma hospitalization history.
eosinophil levels (but were required to have ≥1 systemic corticosteroid burst therapy or ≥1 hospital admission or emergency department/urgent care visit that required systemic steroids in the previous year) showed that the subgroup of patients with baseline eosinophil count <300/lL who received dupilumab 200 mg or 300 mg every 2 weeks had exacerbation risk reductions vs placebo of 67.6% (P = .0081) and 59.9% (P = .0152), respectively.
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Given the variability in study design, patient inclusion criteria, study duration, dosing schedules, and biomarker requirements across the various biologic therapies for asthma, it is difficult to directly compare their efficacy. However, the findings of this post hoc study demonstrating an improved and comparable response to omalizumab in patients with a history of asthma hospitalization or emergency department visits, and in those with high baseline blood eosinophil counts, are particularly noteworthy given that the trials for omalizumab were not enriched for these factors, unlike the studies of other biologic therapies; enrichment inherently allows for greater efficacy because patients with more severe asthma and more frequent exacerbations have more room for improvement. This finding also is important within the concept of an eosinophilic asthma phenotype, because omalizumab is not thought to work directly through inhibition of eosinophils. However, omalizumab has been reported to however, these patients were being treated with ICS recommended as primary controller therapy by all guidelines at the time. In addition, the observation period of this study was relatively short 
